news-med.jpg

Evotec and Novo Nordisk form strategic research alliance in diabetes and obesity

The alliance builds upon Evotec's leading drug discovery and development capabilities in diabetes and related co-morbidities Novo Nordisk accesses Evotec's integrated discovery and development platform to progress new molecules from concept to IND including Evotec's INDiGO platform

Topics: Corporate, Drug Development, Drug Discovery, Evotec, diabetes, Novo Nordisk, Obesity Read More